AhR Modulating Agent for the Topical Therapy of Plaque Psoriasis

Treatment of psoriasis is guided mainly by the severity of disease as measured by the Psoriasis Area Severity Index (PASI) and by subjective evaluation as assessed with patient-reported outcome scales. Systemic therapy is used in patients with moderate-to-severe disease and in those with joint involvement (psoriatic arthritis).1 Progress in understanding the pathophysiology of psoriasis led to the development of an impressive number of systemic therapies, including small molecules (e.g., the phosphodiesterase 4 inhibitor apremilast) for oral administration and more than a dozen biologic agents targeting cytokines or their receptors. In contrast, treatments for mild-to-moderate psoriasis have been limited to historically . . .